Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9473123rdf:typepubmed:Citationlld:pubmed
pubmed-article:9473123lifeskim:mentionsumls-concept:C0205145lld:lifeskim
pubmed-article:9473123lifeskim:mentionsumls-concept:C0026457lld:lifeskim
pubmed-article:9473123lifeskim:mentionsumls-concept:C0072892lld:lifeskim
pubmed-article:9473123lifeskim:mentionsumls-concept:C1325847lld:lifeskim
pubmed-article:9473123lifeskim:mentionsumls-concept:C0332324lld:lifeskim
pubmed-article:9473123pubmed:issue2-3lld:pubmed
pubmed-article:9473123pubmed:dateCreated1998-3-26lld:pubmed
pubmed-article:9473123pubmed:abstractTextClorgyline (1.0 mg/kg/day) administered via osmotic minipumps blocked the development of locomotor sensitization to the dopamine receptor agonist quinpirole (0.5 mg/kg every 3 days for 8 injections). In male rats already well sensitized to quinpirole, the continuous infusion of clorgyline (1.0 mg/kg/day for 28 days) produced a progressive decline in locomotor activity, despite a continued regimen of quinpirole injections (0.5 mg/kg every 3 days). It is suggested that the development, as well as the maintenance, of locomotor sensitization to quinpirole is modulated by the activation of an monoamine oxidase inhibitor-sensitive site. This site may be a dopamine D2 receptor-linked monoamine oxidase inhibitor-displaceable quinpirole binding site, the enzyme monoamine oxidase-A, or other clorgyline binding sites.lld:pubmed
pubmed-article:9473123pubmed:languageenglld:pubmed
pubmed-article:9473123pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9473123pubmed:citationSubsetIMlld:pubmed
pubmed-article:9473123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9473123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9473123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9473123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9473123pubmed:statusMEDLINElld:pubmed
pubmed-article:9473123pubmed:monthNovlld:pubmed
pubmed-article:9473123pubmed:issn0014-2999lld:pubmed
pubmed-article:9473123pubmed:authorpubmed-author:SzechtmanHHlld:pubmed
pubmed-article:9473123pubmed:authorpubmed-author:CulverK EKElld:pubmed
pubmed-article:9473123pubmed:issnTypePrintlld:pubmed
pubmed-article:9473123pubmed:day27lld:pubmed
pubmed-article:9473123pubmed:volume339lld:pubmed
pubmed-article:9473123pubmed:ownerNLMlld:pubmed
pubmed-article:9473123pubmed:authorsCompleteYlld:pubmed
pubmed-article:9473123pubmed:pagination109-11lld:pubmed
pubmed-article:9473123pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9473123pubmed:meshHeadingpubmed-meshheading:9473123-...lld:pubmed
pubmed-article:9473123pubmed:meshHeadingpubmed-meshheading:9473123-...lld:pubmed
pubmed-article:9473123pubmed:meshHeadingpubmed-meshheading:9473123-...lld:pubmed
pubmed-article:9473123pubmed:meshHeadingpubmed-meshheading:9473123-...lld:pubmed
pubmed-article:9473123pubmed:meshHeadingpubmed-meshheading:9473123-...lld:pubmed
pubmed-article:9473123pubmed:meshHeadingpubmed-meshheading:9473123-...lld:pubmed
pubmed-article:9473123pubmed:meshHeadingpubmed-meshheading:9473123-...lld:pubmed
pubmed-article:9473123pubmed:meshHeadingpubmed-meshheading:9473123-...lld:pubmed
pubmed-article:9473123pubmed:meshHeadingpubmed-meshheading:9473123-...lld:pubmed
pubmed-article:9473123pubmed:year1997lld:pubmed
pubmed-article:9473123pubmed:articleTitleMonoamine oxidase inhibitor sensitive site implicated in sensitization to quinpirole.lld:pubmed
pubmed-article:9473123pubmed:affiliationDepartment of Biomedical Sciences, McMaster University, Hamilton, Ont., Canada.lld:pubmed
pubmed-article:9473123pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9473123pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9473123lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9473123lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9473123lld:pubmed